TICKERNERD
Menu
DYAIDYAIHealthcare · Biotechnology

DYAI Stock Forecast: Dyadic International, Inc. Price Predictions for 2026-2027

Last close, 7 Oct 2026
$0.46
+1.44% on the day

The 1 Wall Street analysts covering Dyadic International, Inc. hold a median 12-month price target of $5.5 — +1104.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 16 of 100 as at 6 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$18.0M
Ticker Nerd rank
16 / 100
Median analyst target
$5.50
Analysts covering
1
Revenue$124K−73.3% y/y
Operating income−$2.0M
Net income−$2.1M
Free cash flow−$1.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+3.8%
1M
−12.2%
YTD
−51.4%
1Y
−60.0%
From 52W high
−68.9%
From 52W low
+14.1%
$0.40
$1.47
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

DYAI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Dyadic International, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 6 Oct 2026
16 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
89
Volatility
50
Issuance
44
Accruals
43
Value
32
Revisions
26
Growth
24
Quality
13
Momentum
9

Size (89): Smaller than most of the companies we track.

Momentum (9): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

DYAI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on DYAI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00Jan 26Apr 26Jul 26Oct 26DYAIHigh $7.00Median $5.50Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $4.00Median $5.50High $7.00

The green dot is the last close — the median target sits +1104.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
23 Oct 2025HC Wainwright & Co.AssumesBuy$3.00
14 Nov 2024HC Wainwright & Co.ReiteratesBuy—
8 July 2024HC Wainwright & Co.ReiteratesBuy—
13 Nov 2023HC Wainwright & Co.ReiteratesBuy—
24 May 2023HC Wainwright & Co.ReiteratesBuy—
3 Feb 2023HC Wainwright & Co.ReiteratesBuy—
18 July 2022Dawson JamesDowngradeNeutral—
5 Apr 2022HC Wainwright & Co.MaintainsBuy—
17 Dec 2021HC Wainwright & Co.InitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DYAI appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

DYAI vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 7 Oct 2026, Dyadic International, Inc. returned −60.0% against +17.7% for the S&P 500, dividends included.

DYAI vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26DYAIS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

DYAI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Dyadic International, Inc. (DYAI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.0×

Cheaper than 86% of US stocks

Price / sales
4.8×

Cheaper than 25% of US stocks

Price / book
−6.9×

Cheaper than 97% of US stocks

EV / EBITDA
−2.7×

Cheaper than 75% of US stocks

Growth & margins
Revenue growth (YoY)
−0.6%

Higher than 27% of US stocks

Earnings growth (YoY)
−73.3%

Higher than 6% of US stocks

Gross margin
−694.4%

Higher than 1% of US stocks

Operating margin
−212.8%

Higher than 11% of US stocks

Net margin
−200.5%

Higher than 3% of US stocks

Returns & dividend
Return on equity
−597.6%

Higher than 3% of US stocks

Return on assets
−63.0%

Higher than 6% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Dyadic International, Inc. (DYAI) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Dyadic International, Inc. has a market value of $18.0M and an enterprise value of $18.5M.

  • Revenue in the twelve months to 30 June 2026: $1.3M. The latest quarter shrank 0.6% year on year.

  • Net income over the same four quarters: −$7.6M, a −571.7% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$7.4M.

  • Shares outstanding: 36.4M.

  • Trailing P/E: −2.0×; forward P/E: −1.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Dyadic International, Inc. employs 5 people — $267K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

DYAI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
DYAIDyadic International, Inc.$18.0M
16
ESLAEstrella Immunopharma, Inc.$18.0M
22
TCRXTScan Therapeutics, Inc.$18.0M
55
NEUPNeuphoria Therapeutics, Inc.$18.6M
6
JSPRJasper Therapeutics, Inc.$18.6M
39
PBMPsyence Biomedical Ltd.$19.1M
4
ACTUActuate Therapeutics, Inc.$19.5M
35

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Dyadic International, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest DYAI news & analysis

Dyadic International, Inc. (DYAI) Presents at IAccess Alpha Virtual Best Ideas Fall Investment Conference 2026 Transcript

Seeking Alpha · 15 Sept 2026neutral

Dyadic International presented at the IAccess Alpha Virtual Best Ideas Fall Investment Conference 2026, with a transcript of the presentation made available by Seeking Alpha. The presentation is part of Dyadic's investor outreach at a virtual investment conference.

Why it matters — DYAI watchers would care because the presentation provides insight into the company's current operations and outlook as communicated directly to investors at a conference.

Dyadic International, Inc. Secures $2.9 Million Through Registered Direct Offering and Concurrent Private Placement

GlobeNewsWire · 13 Aug 2026neutral

Dyadic International announced definitive agreements with an institutional investor to sell common stock in a registered direct offering and issue warrants in a concurrent private placement, securing $2.9 million. The company is a biotechnology firm developing recombinant protein solutions across life sciences, food and nutrition, bio-industrial and biopharmaceutical markets.

Why it matters — DYAI watchers would care because this capital raise adds funding to the company through the sale of new shares and warrants.

Dyadic International, Inc. (DYAI) Q2 2026 Earnings Call Transcript

Seeking Alpha · 13 Aug 2026neutral

Seeking Alpha published the transcript of Dyadic International, Inc.'s (DYAI) Q2 2026 earnings call. The item discloses that the company held its second-quarter earnings call and that the full transcript is now available.

Why it matters — Investors following DYAI can review the official earnings call transcript for management's commentary on the company's quarterly performance.

Dyadic Announces Second Quarter 2026 Financial Results Accelerating Commercialization Momentum Across Key Business Areas

GlobeNewsWire · 12 Aug 2026positive

Dyadic International reported its financial results for the second quarter ended June 30, 2026, highlighting significant progress in product commercialization, strategic partnerships, and expansion of its C1 biomanufacturing platform.

Why it matters — The Q2 2026 results provide DYAI watchers with an update on the company's commercialization momentum and strategic progress across its key business areas.

Dyadic Expands Commercial Non-Animal Dairy Pipeline Through New Strategic Development Agreement

GlobeNewsWire · 4 Aug 2026positive

Dyadic announced a new development and commercial license agreement with a European biotechnology company to add precision-fermented dairy proteins to its commercial non-animal dairy pipeline. The agreement expands Dyadic's offerings in the food and nutrition market.

Why it matters — A DYAI watcher would care because the agreement expands Dyadic's commercial non-animal dairy pipeline through a new partnership, broadening its reach in the food and nutrition sector.

FAQ

Frequently asked questions about DYAI stock

What is the DYAI stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Dyadic International, Inc. have a median 12-month price target of $5.5, with estimates ranging from $4 to $7. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is DYAI stock a buy right now?

Of the 1 analysts covering Dyadic International, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Dyadic International, Inc. 16 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank DYAI?

As at 6 Oct 2026, Dyadic International, Inc. ranks 16 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (89 of 100).

Will DYAI stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +1104.8% from the last close, and Ticker Nerd's factor model ranks Dyadic International, Inc. 16 out of 100 as at 6 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the DYAI stock forecast for 2030?

No analyst covering Dyadic International, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DYAI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $7 over the next 12 months.

How has DYAI stock performed over the past year?

Dyadic International, Inc. returned -60.0% over the 12 months to 7 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Dyadic International, Inc. do?

Dyadic International, Inc. is a biotechnology company focused on scalable protein production for non-pharmaceutical applications.

What is the latest news on DYAI?

The most recent item we track (Seeking Alpha, 15 Sept 2026): "Dyadic International, Inc. (DYAI) Presents at IAccess Alpha Virtual Best Ideas Fall Investment Conference 2026 Transcript". Dyadic International presented at the IAccess Alpha Virtual Best Ideas Fall Investment Conference 2026, with a transcript of the presentation made available by Seeking Alpha. The presentation is part of Dyadic's investor outreach at a virtual investment conference.

Company

About Dyadic International, Inc.

Dyadic International, Inc. is a biotechnology company focused on scalable protein production for non-pharmaceutical applications. Through its proprietary C1 and Dapibus expression platforms, Dyadic develops and commercializes precision-engineered proteins and enzymes used in life sciences, food and nutrition, and industrial biotechnology. Its technology is designed to support the efficient manufacture of recombinant, animal-free inputs that can be sold directly or licensed to partners across multiple markets. The company’s current business centers on producing functional proteins for customers seeking flexible, cost-effective biomanufacturing solutions in areas such as specialty ingredients, enzyme development, and other bioindustrial uses. Dyadic International, Inc. is headquartered in Jupiter, Florida, and operates as a global biotechnology platform company serving commercial and research-oriented applications.

CEO Mr. Mark A. Emalfarb · 5 employees · United States · https://www.dyadic.com